TY - JOUR
T1 - Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers
T2 - A Gynecologic Oncology Group study
AU - Markman, Maurie
AU - Blessing, John A.
AU - Rubin, Stephen C.
AU - Connor, Joseph
AU - Hanjani, Parviz
AU - Waggoner, Steven
PY - 2006/6
Y1 - 2006/6
N2 - Objective.: To evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks)-resistant ovarian cancer. Methods.: Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence <6 months following, their prior treatment with both agents) received single agent weekly paclitaxel (80 mg/m2/week) until disease progression (assuming acceptable toxicity). Following the initial 12 weekly doses, treatment could be given for 3 weeks, with a 1 week break. Results.: In this chemoresistant population, the objective response rate was 20.9%. Serious adverse events were relatively uncommon (neuropathy-grade 2: 21%; grade 3: 4%; and grade 3 fatigue: 8%). Conclusion.: The weekly administration of paclitaxel can be a useful management approach in women with both platinum and paclitaxel (given every 3 weeks)-resistant ovarian cancer. It would be appropriate to directly compare weekly to every 3-week paclitaxel delivery in the setting of primary chemotherapy of advanced ovarian cancer.
AB - Objective.: To evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks)-resistant ovarian cancer. Methods.: Forty-eight patients with platinum and paclitaxel-resistant ovarian cancer (defined as progression during, or recurrence <6 months following, their prior treatment with both agents) received single agent weekly paclitaxel (80 mg/m2/week) until disease progression (assuming acceptable toxicity). Following the initial 12 weekly doses, treatment could be given for 3 weeks, with a 1 week break. Results.: In this chemoresistant population, the objective response rate was 20.9%. Serious adverse events were relatively uncommon (neuropathy-grade 2: 21%; grade 3: 4%; and grade 3 fatigue: 8%). Conclusion.: The weekly administration of paclitaxel can be a useful management approach in women with both platinum and paclitaxel (given every 3 weeks)-resistant ovarian cancer. It would be appropriate to directly compare weekly to every 3-week paclitaxel delivery in the setting of primary chemotherapy of advanced ovarian cancer.
KW - Chemotherapy of ovarian cancer
KW - Ovarian cancer
KW - Paclitaxel-resistant ovarian cancer
KW - Platinum-resistant ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=33646562149&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2005.10.036
DO - 10.1016/j.ygyno.2005.10.036
M3 - Article
C2 - 16325893
SN - 0090-8258
VL - 101
SP - 436
EP - 440
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -